News

What happened, reported straight.

A Protein Clog in the Brain's Pipes May Explain Who Dodges Alzheimer's Damage

Columbia researchers report that fibronectin, a structural protein, piles up around brain blood vessels in carriers of the Alzheimer's risk gene APOE4 and wears down the barrier that protects the brain. A rare genetic variant tied to protection in those same carriers appears to work by keeping that pileup in check.

Split the Same Blood Sample Between Two Labs and the Numbers Don't Match

A pilot analysis from the University of Washington Alzheimer's Disease Research Center split nearly 200 plasma samples between a national lab and its own, and the national lab's numbers ran consistently higher, even as the two sets of results tracked each other closely. The National Alzheimer's Coordinating Center reported the finding this month.

A Brain Autopsy Finds a Border Between Where Amyloid Left and Where It Stayed

Pathologists at the University of Pennsylvania examined the donated brain of a man who took the anti-amyloid drug aducanumab for four and a half years. Where the drug had cleared plaque most thoroughly, tau tangles and tissue loss ran markedly lower than in neighboring patches of the same brain where amyloid never left.

UCSF Points a PET Scanner at the Brain's Support Cells, Not Its Plaques

A first-in-human trial at the University of California, San Francisco is imaging a transporter that sits almost entirely on astrocytes, the brain's housekeeping cells, to see whether their decline shows up before amyloid or tau does. So far, the only published results confirm the tracer is safe to give.

The ZIP Code Shows Up on the Scan

A look at 1,110 people enrolled in the Alzheimer's Disease Neuroimaging Initiative found that those living in more economically deprived neighborhoods scored lower on a standard cognition test, and, among those with no signs of impairment, carried more amyloid protein on PET scans. The study is observational. It does not show that where someone lives causes amyloid to build up.

Leqembi's At-Home Starting Dose Reaches Patients as China Clears Same Shot

Six weeks after the FDA cleared it, Eisai says the subcutaneous Leqembi Iqlik autoinjector is now available in the United States as a starting dose for early Alzheimer's disease, and China has approved the same formulation for initiation treatment, extending how much of the drug course can be given by injection at home rather than by IV infusion.

Sporadic CJD Confirmed in Hunter; CWD Link Not Found

A peer-reviewed case report describes a Louisiana hunter's fatal, laboratory-confirmed sporadic Creutzfeldt-Jakob disease and the public health investigation triggered when a hunting-lodge peer developed similar illness; investigators found no evidence tying the cases to chronic wasting disease in local deer.

Global tally of frontotemporal dementia drug trials: just twelve

A scoping review of three international trial registries found only twelve interventional studies worldwide testing disease-modifying drugs for frontotemporal dementia, split evenly between gene therapies for a rare inherited form and anti-inflammatory drugs aimed at the more common sporadic disease.

New estimate: APOE gene accounts for most Alzheimer's cases

A four-cohort genetic-epidemiology analysis calculates that the common APOE variants underlie roughly three-quarters to over nine-tenths of Alzheimer's disease cases, and close to half of all-cause dementia, a larger share than earlier estimates suggested.